EX-99.1
3
a05-15570_1ex99d1.htm
EX-99.1
Exhibit 99.1
For More Information:
Pam Sullivan
Brian Gendron
Phase Forward
SHIFT Communications
781-902-4502
617-681-1226
pam.sullivan@phaseforward.com
bgendron@shiftcomm.com
Karen Vahouny
Qorvis Communications
703-744-7809
kvahouny@qorvis.com
PHASE FORWARD COMPLETES LINCOLN TECHNOLOGIES
ACQUISITION
Waltham,
MA - August 25, 2005
- Phase Forward (NASDAQ: PFWD), a leading provider of data management
solutions for clinical trials and drug safety, today announced that it has completed
the previously announced acquisition of privately held Lincoln Technologies,
Inc. in an all-cash transaction valued at $11 million, plus up to an additional
$6 million based on achievement of certain financial targets in 2005 and 2006.
Based in Wellesley, Massachusetts, Lincoln Technologies is recognized as a
market-leading provider of products and services for strategic
pharmacovigilance, clinical trial safety signal detection, and applied data
standards. Lincoln's key customers include major pharmaceutical companies in
the U.S. and Europe. In addition,
Lincoln has relationships with key government and health regulatory agencies
including the FDA in the U.S. and the MHRA in the United Kingdom. Lincoln
Technologies will retain its name and will continue to be managed by its
current president, Chan Russell.
About
Phase Forward
Phase Forward is a leading provider of integrated data management solutions for
clinical trials and drug safety. The company helps pharmaceutical,
biotechnology, and medical device companies bring needed drugs and therapies to
market faster and more safely. Phase Forward offers proven solutions in
electronic data capture (EDC), clinical data management (CDM), and adverse
event reporting (AER). Phase Forward products and services have been utilized
in over 10,000 clinical trials involving more than 1,000,000 clinical trial
study participants at over 220 organizations worldwide including: AstraZeneca,
Biogen Idec, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, GlaxoSmithKline,
Guidant, Procter & Gamble, Quintiles, Sanofi-Aventis, Schering-Plough
Research Institute, and Serono. Additional information about Phase Forward is
available at www.phaseforward.com.

EX - 99 . 1 3 a05 - 15570 _ 1ex99d1 . htm EX - 99 . 1 Exhibit 99 . 1 For More Information : Pam Sullivan Brian Gendron Phase Forward SHIFT Communications 781 - 902 - 4502 617 - 681 - 1226 pam.sullivan@phaseforward.com bgendron@shiftcomm.com Karen Vahouny Qorvis Communications 703 - 744 - 7809 kvahouny@qorvis.com PHASE FORWARD COMPLETES LINCOLN TECHNOLOGIES ACQUISITION Waltham , MA - August 25 , 2005 - Phase Forward ( NASDAQ : PFWD ) , a leading provider of data management solutions for clinical trials and drug safety , today announced that it has completed the previously announced acquisition of privately held Lincoln Technologies , Inc . in an all - cash transaction valued at $ 11 million , plus up to an additional $ 6 million based on achievement of certain financial targets in 2005 and 2006 . Based in Wellesley , Massachusetts , Lincoln Technologies is recognized as a market - leading provider of products and services for strategic pharmacovigilance , clinical trial safety signal detection , and applied data standards . Lincoln 's key customers include major pharmaceutical companies in the U . S . and Europe . In addition , Lincoln has relationships with key government and health regulatory agencies including the FDA in the U . S . and the MHRA in the United Kingdom . Lincoln Technologies will retain its name and will continue to be managed by its current president , Chan Russell . About Phase Forward Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety . The company helps pharmaceutical , biotechnology , and medical device companies bring needed drugs and therapies to market faster and more safely . Phase Forward offers proven solutions in electronic data capture ( EDC ) , clinical data management ( CDM ) , and adverse event reporting ( AER ) . Phase Forward products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 220 organizations worldwide including : AstraZeneca , Biogen Idec , Boston Scientific , Dana - Farber Cancer Institute , Eli Lilly , GlaxoSmithKline , Guidant , Procter & Gamble , Quintiles , Sanofi - Aventis , Schering - Plough Research Institute , and Serono . Additional information about Phase Forward is available at www.phaseforward.com .